Terkko Navigator / Leukemia

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability

Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL

De novo gene mutations in normal human memory B cells

Targeting MEK in vemurafenib-resistant hairy cell leukemia

SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis

Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies

DUX4HD2-DNAERG structure reveals new insight into DUX4-Responsive-Element

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia

Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure

The NF1 hotspot in acute myeloid leukemia: what’s in a name?

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues

Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel et al.

Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis

Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics

Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?

Combining bh3-Mimetics to target both bcl-2 and mcl1 has potent activity in pre-clinical models of acute myeloid leukemia

Characterization of an X-chromosome-linked telomere biology disorder in females with DKC1 mutation

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

miR-22 suppresses DNA ligase III addiction in multiple myeloma

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study

The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia

P2X7 polymorphisms and stem cell mobilisation

TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1α stabilization

Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32